Phase II trial of Echinomycin in advanced hormone-resistant prostate cancer: An Illinois Cancer Council study
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Clinical development of echinomycin was discontinued because it was not effective for patients with solid tumors refractory to all available treatments.
“However, clinical development was discontinued because echinomycin was not found to be effective for patients with solid tumors that were refractory to all available treatments.”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [13]
Cites
Echinomycin: a bifunctional intercalating antibiotic
Waring, M. J., & Wakelin, L. P. G. (1974) · Nature · doi:10.1038/252653a0 · Cited by 284 · see citing works
Structure of quinomycin antibiotics.
Martin, D. G., MIZSAK, S. A., Biles, C., STEWART, J. C., Baczynskyj, L., & Meulman, P. A. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.332 · Cited by 56 · see citing works
DNA bis‐intercalation: Application of theory to the binding of echinomycin to DNA
Shafer, R. H., & Waring, M. J. (1980) · Biopolymers · doi:10.1002/bip.1980.360190216 · Cited by 21 · see citing works
Phase I study of echinomycin administered on an intermittent bolus schedule.
Jh, H., McFadden, M., Andrews, W. G., Pj, B., Ahlgren, J. D., & Pv, W. (1985) · PubMed · Cited by 16 · see citing works
Cytotoxic Activity of Echinomycin in a Human Tumor Cloning System
Lathan, B., & Hoff, D. D. V. (1984) · Cancer Drug Delivery · doi:10.1089/cdd.1984.1.191 · Cited by 14 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Bui, B. P., Nguyen, P. L., Lee, K., & Cho, J. (2022) · Cancers · doi:10.3390/cancers14246054 · Cited by 164 · see citing works
Wang, Y., Liu, Y., Tang, F., Bernot, K. M., Schore, R., Marcucci, G., Caligiuri, M. A., Zheng, P., & Liu, Y. (2014) · Blood · doi:10.1182/blood-2013-12-544221 · Cited by 69 · see citing works
Alshaer, W., Zraikat, M. S., Amer, A., Nsairat, H., Lafi, Z., Alqudah, D. A., Qadi, E. A., Alsheleh, T., Odeh, F., Alkaraki, A., et al. (2019) · RSC Advances · doi:10.1039/c9ra05636j · Cited by 65 · see citing works
Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells
Ponnurangam, S., Dandawate, P. R., Dhar, A., Tawfik, O. W., Parab, R., Mishra, P. D., Ranadive, P., Sharma, R. K., Mahajan, G., Umar, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6560 · Cited by 64 · see citing works
Gradishar, W. J., Vogelzang, N. J., Kilton, L. J., Leibach, S. J., Rademaker, A. W., French, S., & Benson, A. B. (1995) · Investigational New Drugs · doi:10.1007/bf00872868 · Cited by 49 · see citing works
Notch signaling, hypoxia, and cancer
Guo, M., Niu, Y., Xie, M., Liu, X., & Li, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1078768 · Cited by 48 · see citing works
Bailey, C. M., Liu, Y., Peng, G., Zhang, H., He, M., Sun, D., Zheng, P., Liu, Y., & Wang, Y. (2020) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2020.102278 · Cited by 44 · see citing works
Chen, M., Zeng, J., Ruan, W., Zhang, Z., Wang, Y., Xie, S., Wang, Z., & Yang, H. (2020) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.11.45 · Cited by 26 · see citing works
Total Synthesis of Echinomycin and Its Analogues
Kojima, K., Yakushiji, F., Katsuyama, A., & Ichikawa, S. (2020) · Organic Letters · doi:10.1021/acs.orglett.0c01268 · Cited by 18 · see citing works
Chen, C., Chen, X., Ren, B., Guo, H., Abdel-Mageed, W. M., Liu, X., Song, F., & Zhang, L. (2021) · Journal of Industrial Microbiology & Biotechnology · doi:10.1093/jimb/kuab079 · Cited by 14 · see citing works
Quinomycin A reduces cyst progression in polycystic kidney disease
Radadiya, P. S., Thornton, M. M., Daniel, E. A., Idowu, J. Y., Wang, W., Magenheimer, B. S., Subramaniam, D., Tran, P. V., Calvet, J. P., Wallace, D. P., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202002490r · Cited by 12 · see citing works
Targeting the SMURF2-HIF1α axis: a new frontier in cancer therapy
Youssef, E. M., Zhao, S., Purcell, C., Olson, G. L., & El‐Deiry, W. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1484515 · Cited by 10 · see citing works
Endophytic Microbes from Medicinal Plants in Fenghuang Mountain as a Source of Antibiotics
Yang, A., Hong, Y., Zhou, F., Zhang, L., Zhu, Y., Wang, C., Hu, Y., Yu, L., Chen, L., & Wang, X. (2023) · Molecules · doi:10.3390/molecules28176301 · Cited by 9 · see citing works
Xu, L., Ishikawa, H., Zhou, Y., Kobayashi, T., & Shozu, M. (2022) · F&S Science · doi:10.1016/j.xfss.2022.01.005 · Cited by 6 · see citing works
Synthesis and biological evaluation of echinomycin analogues as potential colon cancer agent
Kojima, K., Konishi, H., Momosaki, K., Komatani, Y., Katsuyama, A., Nakagawa, K., Kanamitsu, K., Yakushiji, F., Fujiya, M., & Ichikawa, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-58196-3 · Cited by 5 · see citing works
The bisintercalator family of nonribosomal peptides: structural diversity and biosynthetic mechanism
Shi, X. (2025) · Natural Product Reports · doi:10.1039/d5np00003c · Cited by 2 · see citing works
Treatment of Graft-versus-Host Disease by Echinomycin in a New Humanized Mouse ModelPreprint
Liu, Y., Bailey, C. M., Lazarski, C. A., Wong, C.-S., Zheng, P., Liu, Y., & Wang, Y. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/108951 · Cited by 2 · see citing works
- Authors
- Shevrin, D. H., Lad, T. E., Guinan, P., Kilton, L. J., Greenburg, A., Johnson, P., Blough, R. R., & Hoyer, H.
- Affiliations
- Evanston Hospital (US)
- University of Illinois Hospital & Health Sciences System (US)
- John H. Stroger, Jr. Hospital of Cook County (US)
- Decatur Memorial Hospital (US)
- Carle Foundation Hospital (US)
- Venue
- Investigational New Drugs
- Published
- 1994-03
- Volume
- 12
- Issue
- 1
- Pages
- 65-66
- ISSN
- 0167-6997 (ISSN-L)
- 1573-0646
- OpenAlex
- W2318295331
- Cited by
- 17
- References
- 5
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 1 · 2017: 1 · 2015: 1 · 2014: 1
- FWCI
- 0.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Investigational New Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (NCI 2P30-CA-21742, P30CA021742)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
- Keywords
- echinomycin, castration-resistant prostate cancer, advanced prostate cancer, anthracycline chemotherapy
- MeSH terms
- Aged, Drug Resistance, Echinomycin, Hormones, Humans, Injections, Intravenous, Male, Middle Aged, Prostatic Neoplasms, Survival Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
